CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 4.64: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
486.04MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.7220xvs all stocks
52-Week Change
12.82%vs all stocks
Market Capitalization
486.04MUSDvs all stocks (USD)
Enterprise Value
339.15MUSDvs all stocks (USD)
Forward P/E
-5.66xvs Biotechnology peers
Price to Book (MRQ)
1.97xvs Biotechnology peers
Enterprise to EBITDA
-2.55xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-33.63%vs Biotechnology peers
Return on Equity (TTM)
-73.70%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
-99.73MUSDvs all stocks (USD)
EBITDA (TTM)
-133.07MUSDvs all stocks (USD)
Net Income (TTM)
-129.42MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-104.00MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-89.19MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-108.14MUSDvs all stocks (USD)
Pre-tax Income
-105.04MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.60KUSDFY2025 · Dec 31, 2025Net Income
-105.04MUSDFY2025 · Dec 31, 2025EBIT
-102.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-106.21MUSDFY2025 · Dec 31, 2025Research & Development
84.45MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
22.75MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
3.05MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.26USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.26USDFY2025 · Dec 31, 2025Basic Shares Outstanding
46.48MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
46.48MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-105.04MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-71.86MUSDFY2025 · Dec 31, 2025Free Cash Flow
-83.58MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
287.85MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.60KUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-105.04MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.89MUSDFY2025 · Dec 31, 2025Stock-based Compensation
17.23MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.76MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
10.31MUSDFY2025 · Dec 31, 2025Capital Expenditures
-11.72MUSDFY2025 · Dec 31, 2025Purchase of Investments
-151.39MUSDFY2025 · Dec 31, 2025Sale of Investments
260.60MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
97.48MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
237.03MUSDFY2025 · Dec 31, 2025Shares Outstanding
58.11MSharesUpdated Sep 27, 2026Float Shares
42.60MSharesUpdated Sep 27, 2026Shares Short
19.68MSharesUpdated Sep 27, 2026Short Ratio
2.62daysvs all stocks
Short % of Shares Outstanding
37.37%vs all stocks
% Held by Insiders
9.44%vs all stocks
% Held by Institutions
76.46%vs all stocks
Total Cash (MRQ)
237.93MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.09USDUpdated Sep 27, 2026Total Debt (MRQ)
91.05MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3698xvs Biotechnology peers
Current Ratio (MRQ)
7.35xvs Biotechnology peers
Book Value per Share (MRQ)
4.24USDUpdated Sep 27, 2026Total Assets
355.95MUSDvs all stocks (USD)
Total Current Assets
322.94MUSDFY2025 · Dec 31, 2025Total Liabilities
50.16MUSDFY2025 · Dec 31, 2025Total Non-current Assets
33.01MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
14.32MUSDFY2025 · Dec 31, 2025Total Current Liabilities
35.84MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
287.85MUSDFY2025 · Dec 31, 2025Other Short-term Investments
30.28MUSDFY2025 · Dec 31, 2025Accounts Receivable
59.17KUSDFY2025 · Dec 31, 2025Accounts Payable
1.65MUSDFY2025 · Dec 31, 2025Short-term Debt
202.38KUSDFY2025 · Dec 31, 2025Deferred Revenue
12.00MUSDFY2025 · Dec 31, 2025Other Current Liabilities
6.42MUSDFY2025 · Dec 31, 2025Long-term Debt
14.32MUSDFY2025 · Dec 31, 2025Common Stock (Book)
57.37KUSDFY2025 · Dec 31, 2025Retained Earnings
-304.88MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
305.79MUSDvs all stocks (USD)
52-Week Low
2.96USDUpdated Sep 27, 202652-Week High
40.37USDUpdated Sep 27, 202652-Week Change
12.82%vs all stocks
Beta
0.7220xvs all stocks
50-Day MA
9.01USDUpdated Sep 27, 2026200-Day MA
23.25USDUpdated Sep 27, 2026Avg 10-Day Volume
2.70MSharesUpdated Sep 27, 2026Avg 30-Day Volume
8.21MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-2.45USDUpdated Sep 27, 2026Other Income / Expense
6.15MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.64: safe zoneNotable
Altman Z-Score: 4.64
High structural barrier to entryNotable
Barrier to Entry: 4.81
Consistent revenue growth patternNotable
Growth Consistency Score: 1.06
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 35,799,263.917
Companies that share the same coordination system — how they create, deliver, or capture value.
Yungshin Global Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Regenxbio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
NeuroPace Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arvinas Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Assembly Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nanhua Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gansu Longshenrongfa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai ZJ Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kingchem Liaoning Life Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pku Healthcare Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Cabaletta Bio Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
CommScope Holding Company, Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Ies Holdings Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown